MHRA paediatric investigation plan
TREMFYA (GUSELKUMAB)
MHRA paediatric investigation plan MHRA-101725-PIP01-24 · Modification
Key facts
| PIP number | MHRA-101725-PIP01-24 |
|---|---|
| Product names | TREMFYA |
| Active substances | GUSELKUMAB |
| Therapeutic areas | Immunology -Rheumatology-Transplantation |
| Conditions | Treatment of psoriasis |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Compliance check outcome | Full |
| Published | Mar 10, 2025 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: